The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Official Title: A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease
Study ID: NCT04663997
Brief Summary: 177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body. The purpose of this study is to find out whether 177Lu PSMA 617can slow the growth of prostate cancer compared to standard chemotherapy treatment
Detailed Description: The standard or usual treatment for this disease is a chemotherapy drug called docetaxel, given by intravenous every 3 weeks, for up to 12 treatments. 177Lu-PSMA-617 is a new type of therapy for prostate cancer. Laboratory tests show that it may help slow the growth of prostate cancer. 177Lu-PSMA-617 has been shown to shrink tumours in animals and has been studied in limited numbers of men with prostate cancer and seems promising but it is not clear if it can offer better control of prostate cancer compared to docetaxel chemotherapy .
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Cross Cancer Institute, Edmonton, Alberta, Canada
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
London Regional Cancer Program, London, Ontario, Canada
Odette Cancer Centre, Toronto, Ontario, Canada
University Health Network, Toronto, Ontario, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
The Jewish General Hospital, Montreal, Quebec, Canada
Hotel-Dieu de Quebec, Quebec City, Quebec, Canada
CIUSSS de l'Estrie - Centre hospitalier, Sherbrooke, Quebec, Canada
Name: Kim Chi
Affiliation: BCCA - Vancouver Cancer Centre, BC Canada
Role: STUDY_CHAIR
Name: Francois Benard
Affiliation: BCCA - Vancouver Cancer Centre, BC Canada
Role: STUDY_CHAIR
Name: Fred Saad
Affiliation: CHUM-Centre Hospitalier de l'Universite de Montreal, Canada
Role: STUDY_CHAIR